Fresenius Kabi and Vifor Pharma have agreed to create a joint venture in China for intravenous iron products. Fresenius said the joint venture would “combine Vifor Pharma’s leading intravenous drug portfolio for the treatment of iron deficiency with Fresenius Kabi’s strong and long-year presence in the market to benefit both patients and the healthcare system in China,” providing patients with access to “vital blood management treatment.”
Although financial terms of the deal were not disclosed, the firms revealed that the joint company would be 55% owned...





